Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) was downgraded by Zacks Investment Research from a “strong-buy” rating to a “hold” rating in a research note issued to investors on Wednesday.
According to Zacks, “Ohr Pharmaceutical, Inc. is a pharmaceutical company. It is focused on the development of novel therapeutics for the treatment of cancer cachexia, wet form of age-related macular degeneration and ophthalmic neovascularization disorders. Ohr Pharmaceutical, Inc. is headquartered in New York. “
Separately, HC Wainwright set a $10.00 price objective on Ohr Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 16th.
Ohr Pharmaceuticals (NASDAQ:OHRP) last released its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.07) earnings per share for the quarter, beating the consensus estimate of ($0.25) by $0.18.
TRADEMARK VIOLATION WARNING: “Ohr Pharmaceuticals, Inc. (OHRP) Rating Lowered to Hold at Zacks Investment Research” was posted by TrueBlueTribune and is owned by of TrueBlueTribune. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://www.truebluetribune.com/2017/10/13/ohr-pharmaceuticals-inc-ohrp-rating-lowered-to-hold-at-zacks-investment-research.html.
A number of institutional investors have recently made changes to their positions in OHRP. Renaissance Technologies LLC raised its holdings in Ohr Pharmaceuticals by 242.3% in the first quarter. Renaissance Technologies LLC now owns 229,709 shares of the biotechnology company’s stock worth $191,000 after purchasing an additional 162,600 shares in the last quarter. Sabby Management LLC raised its holdings in Ohr Pharmaceuticals by 30.5% in the first quarter. Sabby Management LLC now owns 1,509,315 shares of the biotechnology company’s stock worth $1,253,000 after purchasing an additional 352,922 shares in the last quarter. Cannell Peter B & Co. Inc. bought a new position in Ohr Pharmaceuticals in the second quarter worth about $187,000. Finally, Vanguard Group Inc. raised its holdings in Ohr Pharmaceuticals by 0.7% in the second quarter. Vanguard Group Inc. now owns 812,418 shares of the biotechnology company’s stock worth $520,000 after purchasing an additional 5,481 shares in the last quarter. Institutional investors and hedge funds own 7.02% of the company’s stock.
Ohr Pharmaceuticals Company Profile
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
Receive News & Ratings for Ohr Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.